Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000202341

Medchemexpress LLC Fmoc-val-cit-pab-duocarmycin | 99.4% | 1050.59 g·mol-1 | C58H60ClN7O10 | 5 MG
SDP

Catalog No. 5000202341
Encompass_Preferred

Fmoc-Val-Cit-PAB-duocarmycin is a drug-linker conjugate intended for antibody-drug conjugate (ADC) synthesis. It couples a duocarmycin-based cytotoxic payload to an Fmoc-Val-Cit-PAB cleavable spacer, providing a reagent for linker-payload incorporation during ADC development.

  • Cleavable val-cit-pab spacer for protease-triggered release.
  • Duocarmycin-based cytotoxic payload for potent cell killing.
  • High purity (99.4%) with characterized molecular weight.
  • Supplied as a solid, white to yellow, easy-to-handle material.
  • Storage: powder -20°C; in solvent -80°C for long-term stability.

Catalog No. 50-002-02341 Supplier Medchemexpress LLC Supplier No. HY1265325MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Fmoc-Val-Cit-PAB-duocarmycin is a drug-linker conjugate intended for antibody-drug conjugate (ADC) synthesis. It couples a duocarmycin-based cytotoxic payload to an Fmoc-Val-Cit-PAB cleavable spacer, providing a reagent for linker-payload incorporation during ADC development.

  • Cleavable val-cit-pab spacer for protease-triggered release.
  • Duocarmycin-based cytotoxic payload for potent cell killing.
  • High purity (99.4%) with characterized molecular weight.
  • Supplied as a solid, white to yellow, easy-to-handle material.
  • Storage: powder -20°C; in solvent -80°C for long-term stability.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.